Ovid Therapeutics (OVID) Tax Provisions (2021 - 2022)
Ovid Therapeutics' (OVID) quarterly Tax Provisions came in at $50000.0 in Q1 2022, down 90.01% on a YoY basis from $500277.0 in Q1 2021, and up 114.3% quarter-over-quarter from -$349714.0 in Q4 2021.
Powered by 
Analysis
Ovid Therapeutics (OVID) Tax Provisions (2021 - 2022) Analysis & Trends
Ovid Therapeutics (OVID) has reported Tax Provisions for 2 consecutive years, with $50000.0 the latest figure, recorded in Q1 2022.
- For the quarter ending Q1 2022, Tax Provisions fell 90.01% year-over-year to $50000.0; the trailing twelve-month figure through Dec 2022 stood at $50000.0 (down 96.24% YoY), and the FY2021 full-year result was $1.3 million, changed N/A from the prior year.
- Tax Provisions grew to $50000.0 in Q1 2022 per OVID's latest filing, from -$349714.0 in the prior quarter.
- Across five years, Tax Provisions topped out at $1.5 million in Q2 2021 and bottomed at -$349714.0 in Q4 2021.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 663.08 Bn | 642.33 Bn | 17.26 Bn | 1.21 Bn |
| 2 | AbbVie | 453.04 Bn | 446.51 Bn | 12.70 Bn | 662.00 Mn |
| 3 | Merck | 370.87 Bn | 363.78 Bn | 12.21 Bn | 654.00 Mn |
| 4 | Novartis Ag | 305.29 Bn | 298.00 Bn | 11.24 Bn | -1.01 Bn |
| 5 | Pfizer | 162.10 Bn | 150.70 Bn | 10.94 Bn | -407.00 Mn |
| 6 | Sanofi | 53.95 Bn | 46.98 Bn | 10.79 Bn | -524.23 Mn |
| 7 | Revolution Medicines | 45.00 Bn | 45.00 Bn | - | - |
| 8 | BeOne Medicines | 40.49 Bn | 35.39 Bn | 1.53 Bn | 75.45 Mn |
| 9 | Incyte | 25.47 Bn | 20.94 Bn | 1.57 Bn | 165.91 Mn |
| 10 | Ovid Therapeutics | 517.32 Mn | 400.10 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2022 | 50,000.00 |
| Dec 31, 2021 | -349,714.00 |
| Sep 30, 2021 | -294,829.00 |
| Jun 30, 2021 | 1.47 Mn |
| Mar 31, 2021 | 500,277.00 |